FDA Inspection 1098356 — Carter BloodCare - Baylor

Carter BloodCare - Baylor — FEI 1674451

The FDA completed an inspection of Carter BloodCare - Baylor on July 25, 2019 in Dallas, TX. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 1 citation was issued during this inspection. Product area: Biologics.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
July 25, 2019
Fiscal Year
2019
Product Type
Biologics
Project Area
Blood and Blood Products
Location
Dallas, TX (United States)

Citations

IDCFRDescription
15521 CFR 606.160(b)Required records